Irinotecan Cetuximab Evaluation and the Cetuximab Response Evaluation Among Patients with G13D Mutation.

 

Trial Summary:

Randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS wild-type or G13D mutation

Supported By:

Merck Serono

Eligibility:

Patients with metastatic colorectal cancer with either KRAS WT or KRAS G13D mutation

Registration ID:

ACTRN12612000901808

Participation:

International

Australian Lead Group:

AGITG

Status:

Close out

Activation Date:

01/11/12

Chairs:

Eva Segelov (Australia), Jeremy Shapiro (Australia)

Contact:

icecream@ctc.usyd.edu.au